Celltrion Signs Bio-Similar Supply Contract Worth 73.5 Billion KRW
[Asia Economy Reporter Park Jihwan] Celltrion announced on the 2nd that it has signed a supply contract worth 73.5 billion KRW for biosimilar antibody drugs (Remsima IV, Herzuma, Truxima).
The contract counterpart is Celltrion Healthcare, and the contract period is until November 30.
Hot Picks Today
"How Much Will They Get?" 600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division's 'Three Wallets Under One Roof'
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- "Like Samsung, Us Too"... Performance Bonus Battle Spreads to Principal and Subcontractor Unions with Yellow Envelope Act
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The scale of this contract corresponds to 3.98% of last year's consolidated sales.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing Deeply for Your Vote Really Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
